Accovion, a European CRO based in Eschborn, Germany, has extended its reach into what it terms a “key strategic territory” with a new subsidiary, Accovion Ltd., in Windsor, U.K., according to PharmaTimes.
Not only has the U.K. always been a key strategic territory for the company, but also Accovion’s expanding regulatory portfolio and growing involvement in device pharmacovigilance and health economics meant it was “imperative for us to be firmly implanted in London,” said chief operating officer Ivana Waller.
The company was already established at two locations in Germany as well as in the Czech Republic, Poland, Romania and Russia. The Czech and Russian subsidiaries opened last December.
The U.K. subsidiary, which will be headed up by newly appointed managing director Carl Naraynassamy, “consolidates our presence in Europe and affords us a sure platform to access the considerable local clinical research talent and respond even better to our clients' growing needs,” said Waller.
Accovion’s strategic plan for 2011 includes formalizing activities in a number of other European countries by setting up additional subsidiaries.